1. Home
  2. FTFT vs MBIO Comparison

FTFT vs MBIO Comparison

Compare FTFT & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Future FinTech Group Inc.

FTFT

Future FinTech Group Inc.

HOLD

Current Price

$1.16

Market Cap

6.2M

ML Signal

HOLD

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.61

Market Cap

5.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTFT
MBIO
Founded
N/A
2015
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2M
5.3M
IPO Year
2008
2023

Fundamental Metrics

Financial Performance
Metric
FTFT
MBIO
Price
$1.16
$0.61
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
233.8K
34.2K
Earning Date
05-19-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.99
EPS
N/A
N/A
Revenue
$3,829,805.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
77.46
N/A
52 Week Low
$0.56
$0.53
52 Week High
$4.03
$7.00

Technical Indicators

Market Signals
Indicator
FTFT
MBIO
Relative Strength Index (RSI) 41.98 26.00
Support Level $0.94 $0.53
Resistance Level $1.32 $0.80
Average True Range (ATR) 0.16 0.03
MACD -0.04 -0.01
Stochastic Oscillator 9.97 2.59

Price Performance

Historical Comparison
FTFT
MBIO

About FTFT Future FinTech Group Inc.

Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: